EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Diagnostic performance of [18F]Tetrafluoroborate PET versus 131I scintigraphy in differentiated thyroid cancer: a prospective study

Kerim Sonmezoglu iD, Onur Erdem Sahin iD, Kerem Saglam iD, Emre Karayel iD, Huseyin Pehlivanoglu, Lebriz Uslu-Besli iD, Haluk Burcak Sayman iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-08 · 53 (10) · 5963-5970

DOI: 10.1007/s00259-026-07945-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 26.05.2026. Verfasst von Kerim Sonmezoglu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Kocamustafapaşa Street No: 53, Fatih, Istanbul, 34098…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Positron Emission Tomography Computed Tomography, Boric Acids. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University Cerrahpaşa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Differentiated thyroid cancer (DTC) is primarily evaluated using radioiodine (RAI) scanning; however, this approach is limited by the suboptimal imaging properties of 131 I, the cost and limited availability of 123 I, and restricted access to 124 I. [ 18 F]Tetrafluoroborate (TFB), a PET radiotracer targeting the sodium/iodide symporter, has emerged as a promising alternative. This prospective study assessed the diagnostic performance and biodistribution of TFB PET compared with 131 I scintigraphy in patients with DTC.

Methods

This prospective study enrolled 58 patients with histopathologically confirmed DTC after total or near-total thyroidectomy. Forty-eight patients underwent both TFB PET/CT and 131 I SPECT scintigraphy, while 10 underwent only TFB PET for biodistribution analysis. Patients were stratified into preradioiodine (TFB before 131 I; n = 28) and postradioiodine (TFB after 131 I; n = 20) subgroups based on recent radioiodine administration (either diagnostic or therapeutic) to evaluate the potential stunning effect of 131 I on TFB uptake. Patient- and lesion-based analyses were performed, and agreement was assessed using Cohen’s kappa.

Results

In patient-based analysis, concordance between modalities showed both TFB and 131 I positivity in 20 patients, TFB-only positivity in 1 patient, 131 I-only positivity in 5 patients, and negativity in both modalities in 22 patients, yielding substantial overall agreement (κ = 0.75). Agreement was almost perfect in the preradioiodine group (κ = 0.84) but declined to a moderate level in the postradioiodine group (κ = 0.49). In lesion-based analysis ( n = 56), overall detection rates were comparable (TFB, 85.7% vs. 131 I, 73.2%) but significantly higher for TFB in the preradioiodine group (95.7% vs. 68.1%, p < 0.05). Lesion detection decreased markedly in the postradioiodine group (33.3%), consistent with a stunning effect. Biodistribution analysis showed highest physiological uptake in the stomach, salivary glands, esophagus, nasopharynx and unexpected uterine uptake in Nabothian cysts in 45% of female patients.

Conclusion

TFB PET demonstrates diagnostic accuracy and lesion detection rates comparable to 131 I scintigraphy in DTC. Its diagnostic performance is superior in patients without recent radioiodine administration prior to TFB imaging, whereas lesion detectability decreases after radioiodine administration, likely due to a stunning effect. Therefore, TFB PET represents a promising alternative for disease burden assessment in DTC and warrants further multicenter validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsPositron Emission Tomography Computed TomographyBoric AcidsHumansFemaleProspective StudiesMiddle AgedMaleAdultTissue DistributionAgedRadiopharmaceuticalsBorates

Stichwörter der Autor:innen

Differentiated thyroid cancerPET/CTRadioiodine scintigraphySodium/iodide symporter[18F]Tetrafluoroborate

Substanzen

Iodine Radioisotopesfluoroboric acidIodine-131Boric AcidsRadiopharmaceuticalsBorates

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Kocamustafapaşa Street No: 53, Fatih, Istanbul, 34098, Türkiye.
  • Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Kocamustafapaşa Street No: 53, Fatih, Istanbul, 34098, Türkiye. onur.sahin@iuc.edu.tr.

ORCID-Profile: Kerim Sonmezoglu, Onur Erdem Sahin, Kerem Saglam, Emre Karayel, Lebriz Uslu-Besli, Haluk Burcak Sayman

Förderung

  • Istanbul University Cerrahpaşa

Zitieren

APA

Sonmezoglu, K., Sahin, O. E., Saglam, K., Karayel, E., Pehlivanoglu, H., Uslu-Besli, L., & Sayman, H. B. (2026). Diagnostic performance of [18F]Tetrafluoroborate PET versus 131I scintigraphy in differentiated thyroid cancer: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 53(10), 5963-5970. https://doi.org/10.1007/s00259-026-07945-9

Vancouver

Sonmezoglu K, Sahin OE, Saglam K, Karayel E, Pehlivanoglu H, Uslu-Besli L, et al. Diagnostic performance of [18F]Tetrafluoroborate PET versus 131I scintigraphy in differentiated thyroid cancer: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(10):5963-5970. doi:10.1007/s00259-026-07945-9

BibTeX
@article{Sonmezoglu2026,
  author = {Sonmezoglu, Kerim and Sahin, Onur Erdem and Saglam, Kerem and Karayel, Emre and Pehlivanoglu, Huseyin and Uslu-Besli, Lebriz and Sayman, Haluk Burcak},
  title = {Diagnostic performance of [18F]Tetrafluoroborate PET versus 131I scintigraphy in differentiated thyroid cancer: a prospective study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {10},
  pages = {5963--5970},
  doi = {10.1007/s00259-026-07945-9}
}
Kostenlos starten →